IBJNews

Lilly says experimental diabetes drug outperformed rivals

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. said its experimental diabetes drug dulaglutide lowered blood sugar better than three existing diabetes drugs in three Phase 3 clinical trials.

The announcement, made early Monday, sent stock in Indianapolis-based Lilly up as much as 2.1 percent, to $53.99 per share, before cooling off later in the morning.

Patients receiving once-weekly injections of dulaglutide saw their levels of hemoglobin A1C—a key measure of blood sugar—go down more than patients in the trials taking metformin, Byetta or Januvia.

Lilly said the greater effect of dulaglutide was statistically significant in the trials, which included more than 2,600 patients, but the company did not disclose detailed results from the trials.

Lilly said it would present more data about dulaglutide during medical conferences in 2013 and 2014. Lilly plans to file for regulatory approval of dulaglutide next year.

Analysts expect the drug to hit the market in 2014 or 2015 and become a blockbuster.

Chris Schott, an analyst at JP Morgan Chase, expects dulaglutide to rack up $1.1 billion in sales by 2020. Jami Rubin, a pharmaceutical analyst at Goldman Sachs Group, thinks dulaglutide could hit $1 billion in sales as soon as 2017.

Dulaglutide is known as a glucagon-like peptide, or GLP-1. In 2005, Lilly helped launch the first GLP medicine, Byetta, in partnership with California-based Amylin Pharmaceuticals Inc. The two companies also launched a once-weekly version of Byetta, called Bydureon, last year.

But after a dispute between the two companies last year, Lilly agreed to sell its rights to Byetta and Byrdureon for a $250 million break-up fee and royalties up to $1.2 billion over the life of Byetta. Instead, Lilly decided to bet on dulaglutide.

"We're very encouraged by the results to date from our Phase III dulaglutide trials and are pleased to be one step closer to offering a new GLP-1 treatment option for type 2 diabetes," said Enrique Conterno, president of Lilly’s diabetes division, in a prepared statement.

If approved, dulaglutide would also have to compete with another GLP-1 drug, Victoza, which is made by Denmark-based Novo Nordisk A/S and has proved superior to Byetta.

It would also compete against Januvia, made by New Jersey-based Merck & Co. Inc., which is a popular oral drug that lowers diabetics’ blood sugar. Last year, Lilly launched its own oral diabetes medicine, called Tradjenta, in partnership with Germany-based Boehringer Ingelheim GmbH. Sales of the drug have so far been modest.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I never thought I'd see the day when a Republican Mayor would lead the charge in attempting to raise every tax we have to pay. Now it's income taxes and property taxes that Ballard wants to increase. And to pay for a pre-K program? Many studies have shown that pre-K offer no long-term educational benefits whatsoever. And Ballard is pitching it as a way of fighting crime? Who is he kidding? It's about government provided day care. It's a shame that we elected a Republican who has turned out to be a huge big spending, big taxing, big borrowing liberal Democrat.

  2. Why do we blame the unions? They did not create the 11 different school districts that are the root of the problem.

  3. I was just watching an AOW race from cleveland in 1997...in addition to the 65K for the race, there were more people in boats watching that race from the lake than were IndyCar fans watching the 2014 IndyCar season finale in the Fontana grandstands. Just sayin...That's some resurgence modern IndyCar has going. Almost profitable, nobody in the grandstands and TV ratings dropping 61% at some tracks in the series. Business model..."CRAZY" as said by a NASCAR track general manager. Yup, this thing is purring like a cat! Sponsors...send them your cash, pronto!!! LOL, not a chance.

  4. I'm sure Indiana is paradise for the wealthy and affluent, but what about the rest of us? Over the last 40 years, conservatives and the business elite have run this country (and state)into the ground. The pendulum will swing back as more moderate voters get tired of Reaganomics and regressive social policies. Add to that the wave of minority voters coming up in the next 10 to 15 years and things will get better. unfortunately we have to suffer through 10 more years of gerrymandered districts and dispropionate representation.

  5. Funny thing....rich people telling poor people how bad the other rich people are wanting to cut benefits/school etc and that they should vote for those rich people that just did it. Just saying..............

ADVERTISEMENT